METOPROLOL TARTRATE

Post-LOE

metoprolol tartrate

Baxter

ANDAINJECTIONINJECTABLE

Approved

Apr 2013

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

METOPROLOL TARTRATE (metoprolol tartrate) by Baxter is 1 -selective (cardioselective) adrenergic receptor blocking agent. Approved for definite, suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality. First approved in 2013.

Drug data last refreshed 21h ago

Mechanism of Action

1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…

Indications (2)

definite

Worked on METOPROLOL TARTRATE at Baxter? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

METOPROLOL TARTRATE

Mechanism of Action

Indications (2)

Clinical Trials (1)